{"id":"NCT00021255","sponsor":"Sanofi","briefTitle":"Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer","officialTitle":"Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin and Cyclophosphamide Followed By Docetaxel and Trastuzumab (Herceptin)(AC-TH) and With Docetaxel, Carboplatin and Trastuzumab (TCH) In The Adjuvant Treatment Of Node Positive and High Risk Node Negative Patients With Operable Breast Cancer Containing The HER2 Alteration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-04","primaryCompletion":"2014-12","completion":"2014-12","firstPosted":"2003-01-27","resultsPosted":"2016-11-15","lastUpdate":"2016-11-15"},"enrollment":3222,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms"],"interventions":[{"type":"DRUG","name":"Doxorubicin","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":["Taxotere"]},{"type":"DRUG","name":"Herceptin","otherNames":["Trastuzumab"]},{"type":"DRUG","name":"Carboplatin","otherNames":[]}],"arms":[{"label":"Doxorubicin+Cyclophosphamide (AC) followed by Docetaxel (AC→T)","type":"EXPERIMENTAL"},{"label":"AC followed by Docetaxel + Herceptin (AC→TH)","type":"EXPERIMENTAL"},{"label":"Docetaxel + Carboplatin + Herceptin (TCH)","type":"EXPERIMENTAL"}],"summary":"Primary objective:\n\n* Compare disease-free survival in women with human epidermal growth factor receptor 2 (HER2)-neu-expressing node-positive or high-risk node-negative operable breast cancer treated with adjuvant doxorubicin, cyclophosphamide, and docetaxel with or without trastuzumab (Herceptin) vs trastuzumab, docetaxel, and carboplatin.\n\nSecondary objective:\n\n* Compare overall survival of participants treated with these regimens.\n* Compare the toxic effects (including cardiac) of these regimens in these participants.\n* Compare quality of life of participants treated with these regimens.\n* Compare pathologic and molecular markers for predicting efficacy of these regimens in these participants.\n* For substudy: Compare peripheral levels of shed HER2-neu extracellular domain with fluorescence in situ hybridization in predicting outcome in participants treated with these regimens.","primaryOutcome":{"measure":"Percentage of Participants With Disease Free Survival at 5 Years","timeFrame":"From randomization until relapse or death or up to 5 years","effectByArm":[{"arm":"Doxorubicin+Cyclophosphamide (AC) Followed by Docetaxel (AC→T)","deltaMin":75.5,"sd":null},{"arm":"AC Followed by Docetaxel + Herceptin (AC→TH)","deltaMin":83.2,"sd":null},{"arm":"Docetaxel + Carboplatin + Herceptin (TCH)","deltaMin":81,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":13,"exclusionCount":16},"locations":{"siteCount":42,"countries":["United States","Argentina","Australia","Austria","Belgium","Bosnia and Herzegovina","Brazil","Bulgaria","Canada","Colombia","Croatia","Czechia","Egypt","Estonia","France","Germany","Greece","Hong Kong","Hungary","India","Ireland","Israel","Italy","Lebanon","Mexico","New Zealand","Poland","Romania","Russia","Slovakia","Slovenia","South Africa","South Korea","Spain","Sweden","Switzerland","Taiwan","Tunisia","Turkey (Türkiye)","United Kingdom","Uruguay","Venezuela"]},"refs":{"pmids":["21991949","23814044","23420271","21189395","25649019","27573653"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":218,"n":1018},"commonTop":["ALOPECIA","NAUSEA","ASTHENIA","STOMATITIS","DIARRHEA"]}}